SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 230 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.96 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $75,841,000 | +0.8% | 2,750,856 | +9.9% | 0.10% | +10.5% |
| Q2 2023 | $75,254,000 | -16.0% | 2,503,458 | +1.2% | 0.09% | -18.9% |
| Q1 2023 | $89,636,000 | +3.8% | 2,474,069 | +2.2% | 0.11% | +3.9% |
| Q4 2022 | $86,340,000 | +7.6% | 2,420,534 | +2.1% | 0.10% | +4.1% |
| Q3 2022 | $80,247,000 | +18.7% | 2,370,120 | +1.4% | 0.10% | +28.9% |
| Q2 2022 | $67,595,000 | -9.9% | 2,337,304 | +0.7% | 0.08% | +33.3% |
| Q1 2022 | $74,981,000 | +18.4% | 2,319,950 | +6.8% | 0.06% | +7.5% |
| Q4 2021 | $63,319,000 | +11.1% | 2,171,428 | +1.6% | 0.05% | +8.2% |
| Q3 2021 | $56,995,000 | -13.3% | 2,137,071 | +0.1% | 0.05% | -9.3% |
| Q2 2021 | $65,765,000 | +20.6% | 2,135,923 | +2.5% | 0.05% | -29.9% |
| Q1 2021 | $54,552,000 | -1.9% | 2,083,718 | -5.8% | 0.08% | -4.9% |
| Q4 2020 | $55,633,000 | +30.2% | 2,211,160 | +7.8% | 0.08% | +12.5% |
| Q3 2020 | $42,743,000 | -3.9% | 2,050,999 | +9.6% | 0.07% | -6.5% |
| Q2 2020 | $44,459,000 | +43.0% | 1,871,954 | +8.3% | 0.08% | +20.3% |
| Q1 2020 | $31,092,000 | -12.9% | 1,728,264 | +14.8% | 0.06% | +25.5% |
| Q4 2019 | $35,717,000 | -1.7% | 1,505,820 | +13.9% | 0.05% | -16.4% |
| Q3 2019 | $36,339,000 | -66.1% | 1,322,378 | -59.1% | 0.06% | 0.0% |
| Q2 2019 | $107,115,000 | +207.5% | 3,237,003 | +225.6% | 0.06% | +3.4% |
| Q1 2019 | $34,835,000 | +40.4% | 994,155 | +33.1% | 0.06% | +22.9% |
| Q4 2018 | $24,817,000 | -13.3% | 747,044 | +31.4% | 0.05% | +2.1% |
| Q3 2018 | $28,617,000 | +692.9% | 568,362 | +621.3% | 0.05% | +571.4% |
| Q1 2018 | $3,609,000 | -11.8% | 78,795 | -23.3% | 0.01% | 0.0% |
| Q4 2017 | $4,094,000 | +17.4% | 102,738 | +17.8% | 0.01% | +16.7% |
| Q3 2017 | $3,488,000 | -50.2% | 87,188 | -46.4% | 0.01% | -53.8% |
| Q2 2017 | $7,006,000 | +39.5% | 162,563 | +1.3% | 0.01% | +44.4% |
| Q1 2017 | $5,023,000 | +22.2% | 160,473 | -1.4% | 0.01% | +12.5% |
| Q4 2016 | $4,109,000 | -30.9% | 162,733 | -32.3% | 0.01% | -27.3% |
| Q3 2016 | $5,945,000 | +0.3% | 240,402 | -17.4% | 0.01% | +83.3% |
| Q2 2016 | $5,928,000 | +202.8% | 291,008 | +126.6% | 0.01% | +50.0% |
| Q1 2016 | $1,958,000 | – | 128,400 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 426,500 | $11,754,340 | 3.96% |
| ASHFORD CAPITAL MANAGEMENT INC | 916,747 | $25,274,715 | 3.72% |
| ARMISTICE CAPITAL, LLC | 5,092,000 | $140,386,440 | 2.15% |
| S&T BANK/PA | 215,578 | $5,943 | 1.15% |
| Aristotle Capital Boston, LLC | 1,187,981 | $32,752,634 | 1.06% |
| RICE HALL JAMES & ASSOCIATES, LLC | 544,468 | $15,010,983 | 0.95% |
| Tributary Capital Management, LLC | 352,429 | $9,716,468 | 0.92% |
| Bridge City Capital, LLC | 65,297 | $1,800,238 | 0.91% |
| Integral Health Asset Management, LLC | 220,000 | $6,065,400 | 0.84% |
| Retirement Planning Co of New England, Inc. | 51,608 | $1,422,833 | 0.79% |